Significant Contract Modifications ($10M+) — June 28, 2026

The 10-year firm fixed-price contract provides $85.8M in annualized revenue visibility through 2029, with $457.9M already outlayed, indicating strong government demand for biodefense countermeasures.

The $1.31B defense-related award from DHS represents 52% of total digest value, signaling significant government commitment to SLS Federal Services despite unknown competitive dynamics.

The $339.5M cost-plus award fee contract with CMS has a negative outlay of -$762K, suggesting delayed work, renegotiation, or early-stage termination risk, despite the stable cost-plus structure.

Emergent Biosolutions' $857.6M firm fixed-price contract shifts cost overrun risk to the company; uneven outlay pace ($457.9M of $857.6M outlayed) may signal program delays or production challenges.

CGS Administrators' CMS contract has a negative outlay of -$762K, which could indicate contract termination, renegotiation, or accounting adjustments, posing downside risk for any linked subcontractors.

The digest is heavily concentrated in civilian agencies (DHS and HHS), with no DOD contracts; this limits exposure to defense budget tailwinds and increases vulnerability to civilian budget cuts or CR impacts.

Emergent Biosolutions' $857.6M ACAM2000 contract through 2029 provides a stable revenue base for biodefense investors, with potential upside from option exercises or follow-on smallpox preparedness contracts.

SLS Federal Services' $1.31B DHS contract suggests growing demand for security services; investors should watch for follow-on awards or IDIQ task orders that could expand the company's defense/civilian security footprint.

CGS Administrators' CMS contract, despite negative outlay, operates under cost-plus award fee structure that reduces earnings volatility; if outlay normalizes, the contract could provide stable, low-margin cash flows through 2021.

The $857.6M Emergent Biosolutions contract and $1.31B DHS award total $2.17B in civilian biodefense and security spending, indicating sustained government priority on countermeasures and homeland security despite budget uncertainty.

CGS Administrators' cost-plus award fee contract reduces earnings volatility but caps margin upside, typical of CMS health administration work; this contrasts with Emergent's fixed-price contract which offers higher margin potential but greater execution risk.

{"entity"=>"Emergent Biosolutions", "reason"=>"$857.6M ACAM2000 contract provides 10-year revenue visibility but execution risk is high due to firm fixed-price structure and uneven outlay pace.", "trigger"=>"Option exercise announcements near 2029; HHS/ASPR budget request for biodefense"}

{"entity"=>"SLS Federal Services LLC", "reason"=>"$1.31B DHS contract is the largest in the digest; competitive dynamics and pricing structure are unknown, requiring further disclosure.", "trigger"=>"DHS budget cycle; new task order awards under IDIQ vehicles"}

{"entity"=>"CGS Administrators LLC", "reason"=>"Negative outlay of -$762K on $339.5M CMS contract signals potential underperformance or termination risk.", "trigger"=>"Updated outlay data from USASpending; CMS follow-on award announcements"}